

Supplementary Table 6. Any adverse events in safety population analysis

	Experimental group (N=76)	Control group (N=77)	Total
Total	20 (26.32)	15 (19.48)	35 (22.88)
Gastrointestinal disorders	6 (7.89)	4 (5.19)	10 (6.54)
Gastrointestinal disorder	1 (1.32)	1 (1.30)	2 (1.31)
Gastroesophageal reflux disease	1 (1.32)	1 (1.30)	2 (1.31)
Anal hemorrhage	1 (1.32)	0 (0.00)	1 (0.65)
Constipation	0 (0.00)	1 (1.30)	1 (0.65)
Diarrhea	1 (1.32)	0 (0.00)	1 (0.65)
Dyspepsia	1 (1.32)	0 (0.00)	1 (0.65)
Hemorrhoids	1 (1.32)	0 (0.00)	1 (0.65)
Irritable bowel syndrome	1 (1.32)	0 (0.00)	1 (0.65)
Vomiting	0 (0.00)	1 (1.30)	1 (0.65)
Musculoskeletal and connective tissue disorders	5 (6.58)	2 (2.60)	7 (4.58)
Osteoarthritis	4 (5.26)	0 (0.00)	4 (2.61)
Myalgia	1 (1.32)	1 (1.30)	2 (1.31)
Pain in extremity	0 (0.00)	1 (1.30)	1 (0.65)
Spinal stenosis	1 (1.32)	0 (0.00)	1 (0.65)
Nervous system disorders	4 (5.26)	3 (3.90)	7 (4.58)
Headache	3 (3.95)	1 (1.30)	4 (2.61)
Paraesthesia	1 (1.32)	1 (1.30)	2 (1.31)
Dizziness	0 (0.00)	1 (1.30)	1 (0.65)
Skin and subcutaneous tissue disorders	4 (5.26)	1 (1.30)	5 (3.27)
Urticaria	3 (3.95)	0 (0.00)	3 (1.96)
Eczema nummular	0 (0.00)	1 (1.30)	1 (0.65)
Pruritus	1 (1.32)	0 (0.00)	1 (0.65)
Injury, poisoning, and procedural complications	3 (3.95)	2 (2.60)	5 (3.27)
Ankle fracture	1 (1.32)	0 (0.00)	1 (0.65)
Compression fracture	0 (0.00)	1 (1.30)	1 (0.65)
Contusion	1 (1.32)	0 (0.00)	1 (0.65)
Foot fracture	0 (0.00)	1 (1.30)	1 (0.65)
Skin laceration	1 (1.32)	0 (0.00)	1 (0.65)
Vascular disorders	1 (1.32)	2 (2.60)	3 (1.96)
Peripheral venous disease	1 (1.32)	1 (1.30)	2 (1.31)
Hypertension	0 (0.00)	1 (1.30)	1 (0.65)
General disorders	0 (0.00)	2 (2.60)	2 (1.31)
Pain	0 (0.00)	1 (1.30)	1 (0.65)
Non-cardiac chest pain	0 (0.00)	1 (1.30)	1 (0.65)
Investigations	0 (0.00)	2 (2.60)	2 (1.31)
Alanine aminotransferase increased	0 (0.00)	2 (2.60)	2 (1.31)
Aspartate aminotransferase increased	0 (0.00)	1 (1.30)	1 (0.65)
Ear and labyrinth disorders	2 (2.63)	0 (0.00)	2 (1.31)
Vertigo positional	2 (2.63)	0 (0.00)	2 (1.31)
Infections and infestations	1 (1.32)	1 (1.30)	2 (1.31)
Cystitis	1 (1.32)	0 (0.00)	1 (0.65)
Tinea pedis	0 (0.00)	1 (1.30)	1 (0.65)
Cardiac disorders	0 (0.00)	1 (1.30)	1 (0.65)
Coronary artery stenosis	0 (0.00)	1 (1.30)	1 (0.65)

(Continued to the next page)

Supplementary Table 6. Continued

	Experimental group (N=76)	Control group (N=77)	Total
Eye disorders	1 (1.32)	0 (0.00)	1 (0.65)
Conjunctivitis allergic	1 (1.32)	0 (0.00)	1 (0.65)
Hepatobiliary disorders	1 (1.32)	0 (0.00)	1 (0.65)
Hepatic cyst	1 (1.32)	0 (0.00)	1 (0.65)
Metabolism and nutrition disorders	0 (0.00)	1 (1.30)	1 (0.65)
Hyperlipidemia	0 (0.00)	1 (1.30)	1 (0.65)
Renal and urinary disorders	1 (1.32)	0 (0.00)	1 (0.65)
Renal cyst	1 (1.32)	0 (0.00)	1 (0.65)
Respiratory, thoracic, and mediastinal disorders	0 (0.00)	1 (1.30)	1 (0.65)
Oropharyngeal pain	0 (0.00)	1 (1.30)	1 (0.65)

The data is presented as N (%).